ESALF News and Press, Eisai Co Ltd

"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...

2024-07-11 11:42:26 ET Summary Biogen Inc.'s shares have risen 20% since its first quarter earnings report, with hopes for new product launches to boost revenue. However, its Alzheimer's medicine, Leqembi, now faces new competition from Eli Lilly, and its MS franchise has various ...

"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...

2024-07-07 07:49:00 ET Summary Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. Takeda has made the initial $100 million payment to option global rights (ex-China) for olverembatinib from Ascentage Pharm...

2024-07-04 08:16:04 ET Summary Eisai's story revolves around Leqembi and Lenvima, with Leqembi launching in Japan and expected to reach 10% of necessary revenue for fair value by end of year. Leqembi sales projected to hit 50 billion JPY by March 2025, contributing to fair value t...

2024-07-02 13:54:29 ET More on Eli Lilly 5 Reasons Eli Lilly Just Keeps Rising Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End Eli Lilly, Novo under pressure as Biden urges lower...

Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...

2024-07-01 15:03:10 ET Read the full article on Seeking Alpha For further details see: Eisai receives rights to antibody drug conjugate after Bristol ends collaboration

2024-06-28 06:17:57 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai’s ( OTCPK:ESALF ) ( OTCPK:ESAIY ) breakthrough Alzheimer's therapy, Leqembi (lecanemab), is now available in China, the companies announced late Thursday.... Read the full article ...

Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China TOKYO and CAMBRIDGE, Mass., June 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the humanized anti-soluble aggregated amyloid-beta (Abeta) monoclo...